Cardiovascular Impact of Androgen Deprivation Therapy: from Basic Biology to Clinical Practice.
Androgen deprivation therapy
Cardiovascular complications
Prostate cancer
Testosterone
Journal
Current oncology reports
ISSN: 1534-6269
Titre abrégé: Curr Oncol Rep
Pays: United States
ID NLM: 100888967
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
accepted:
15
04
2023
medline:
5
9
2023
pubmed:
5
6
2023
entrez:
5
6
2023
Statut:
ppublish
Résumé
There have been increasing reports of cardiovascular complications of androgen deprivation therapy (ADT) leading to worse outcomes among patients with prostate cancer. While this may result from the direct effects of androgen suppression in the cardiovascular systems, there are ADT-type-specific distinct cardiovascular complications suggestive of mechanisms beyond androgen-mediated. Thus, it is critical to understand the biological and clinical impact of ADT on the cardiovascular system. Gonadotropin-releasing hormone (GnRH) agonists cause increased cardiovascular events compared to GnRH antagonists. Androgen receptor antagonists are linked to an increased risk of long QT syndrome, torsades de pointes, and sudden cardiac death. Androgen synthesis inhibitors are associated with increased rates of hypertension, atrial tachyarrhythmia, and, in rare incidences, heart failure. ADT increases the risk of cardiovascular disease. The risk among ADT drugs differs and must be evaluated to develop a medically optimal plan for prostate cancer patients.
Identifiants
pubmed: 37273124
doi: 10.1007/s11912-023-01424-2
pii: 10.1007/s11912-023-01424-2
pmc: PMC10474986
doi:
Substances chimiques
Androgens
0
Androgen Antagonists
0
Gonadotropin-Releasing Hormone
33515-09-2
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
965-977Informations de copyright
© 2023. The Author(s).
Références
JACC CardioOncol. 2020 Mar 17;2(1):70-81
pubmed: 34396210
Pharmacotherapy. 2008 Dec;28(12):1511-22
pubmed: 19025432
Acta Pharmacol Sin. 2011 Apr;32(4):537-42
pubmed: 21399652
Ann Oncol. 2020 Sep;31(9):1119-1134
pubmed: 32593798
N Engl J Med. 2020 Jun 4;382(23):2187-2196
pubmed: 32469183
Am J Physiol Endocrinol Metab. 2003 Sep;285(3):E449-53
pubmed: 12684218
Am J Physiol Heart Circ Physiol. 2010 May;298(5):H1382-90
pubmed: 20190100
Vasc Health Risk Manag. 2018 Oct 15;14:283-290
pubmed: 30410343
J Cardiovasc Electrophysiol. 2007 Feb;18(2):196-203
pubmed: 17212595
J Clin Oncol. 2006 Sep 20;24(27):4448-56
pubmed: 16983113
Clin Biochem Rev. 2016 Feb;37(1):3-15
pubmed: 27057074
Cancer. 2021 Jul 1;127(13):2213-2221
pubmed: 33905530
J Endocrinol. 2012 Apr;213(1):77-87
pubmed: 22281525
Am J Mens Health. 2014 Nov;8(6):470-91
pubmed: 24563500
Circulation. 2019 Sep 24;140(13):1070-1080
pubmed: 31378084
Br J Pharmacol. 2008 Feb;153(4):693-709
pubmed: 18157169
Asian J Androl. 2021 Jul-Aug;23(4):348-356
pubmed: 33433530
J Cancer Res Clin Oncol. 2021 Apr;147(4):1217-1226
pubmed: 33000338
Endocr Rev. 2021 May 25;42(3):354-373
pubmed: 33480983
Circulation. 2016 Feb 2;133(5):537-41
pubmed: 26831435
Ann Pharmacother. 2014 Jul 2;48(9):1138-1144
pubmed: 24989174
Int J Mol Sci. 2020 Dec 14;21(24):
pubmed: 33327545
Eur J Clin Pharmacol. 2014 Jul;70(7):791-8
pubmed: 24756149
Sci Rep. 2016 May 18;6:26220
pubmed: 27189011
J Am Coll Cardiol. 2011 Oct 11;58(16):1674-81
pubmed: 21982312
J Clin Endocrinol Metab. 2006 Feb;91(2):546-54
pubmed: 16317058
Arch Cardiovasc Dis. 2020 Jan;113(1):9-21
pubmed: 31685432
Curr Oncol. 2021 Aug 28;28(5):3331-3346
pubmed: 34590590
Int J Mol Sci. 2022 Jan 21;23(3):
pubmed: 35163140
Asian J Androl. 2015 May-Jun;17(3):493-6
pubmed: 25578930
Clin Genitourin Cancer. 2020 Apr;18(2):e157-e166
pubmed: 31956009
Medicine (Baltimore). 2019 Nov;98(44):e17748
pubmed: 31689828
Cancers (Basel). 2019 Dec 23;12(1):
pubmed: 31877956
Arab J Urol. 2019 Nov 13;18(1):9-13
pubmed: 32082628
J Clin Oncol. 2011 Sep 10;29(26):3510-6
pubmed: 21844498
Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):e55-e64
pubmed: 31969015
Oncotarget. 2017 Aug 08;8(48):84572-84578
pubmed: 29137449
Cancer. 2007 Oct 1;110(7):1493-500
pubmed: 17657815
JAMA. 2013 Nov 6;310(17):1829-36
pubmed: 24193080
Am J Physiol Heart Circ Physiol. 2019 Apr 1;316(4):H768-H780
pubmed: 30657724
Anticancer Res. 2017 Mar;37(3):1475-1480
pubmed: 28314320
Circulation. 2010 Feb 16;121(6):833-40
pubmed: 20124128
J Clin Oncol. 2017 Nov 10;35(32):3697-3705
pubmed: 28968166
Sex Med Rev. 2018 Jan;6(1):86-105
pubmed: 29128268
J Urol. 2019 Dec;202(6):1199-1208
pubmed: 31188734
Nat Rev Cardiol. 2019 Sep;16(9):555-574
pubmed: 31123340
Circ Genom Precis Med. 2021 Jun;14(3):e000082
pubmed: 33896190
Front Endocrinol (Lausanne). 2020 May 15;11:316
pubmed: 32499759